Additionally, many LHRH antagonists have been developed and testedfor the treatment of men with advanced prostate cancer such as orgalutran, cetrorelix andabarelix (Schally et al. 2000).An antagonist was considered to be necessary as the superagonists first stimulategonadotropin release (which causes an androgen burst) before a desensitized and refractorystate occurs. The gene discussed is GNRH1; the disease is Familial prostate cancer.